Clinical Trials
9
Active:0
Completed:9
Trial Phases
3 Phases
Phase 2:5
Phase 4:1
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (55.6%)Not Applicable
3 (33.3%)Phase 4
1 (11.1%)A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- Biological: Bevacizumab
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- EPS Corporation
- Target Recruit Count
- 69
- Registration Number
- NCT02246049
- Locations
- 🇯🇵
EPS Corporation, Shinjuku, Tokyo, Japan
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Phase 2
Completed
- Conditions
- Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
- Interventions
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- EPS Corporation
- Target Recruit Count
- 122
- Registration Number
- NCT01836653
- Locations
- 🇯🇵
EPS Corporation, Shinjuku-ku, Tokyo, Japan
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Not Applicable
Completed
- Conditions
- Liver MetastasisColorectal Cancer
- Interventions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- EPS Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT01834014
- Locations
- 🇯🇵
EPS Corporation, Shinjuku-ku, Tokyo, Japan
News
No news found